Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

HEPA - Hepion Pharmaceuticals Inc


IEX Last Trade
0.838
0.038   4.535%

Share volume: 19,875
Last Updated: Fri 30 Aug 2024 09:58:02 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) : 0.87%

PREVIOUS CLOSE
CHG
CHG%

$0.80
0.04
4.75%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
10%
Profitability 0%
Dept financing 10%
Liquidity 50%
Performance 10%
Company vs Stock growth
vs
Performance
5 Days
10.26%
1 Month
5.81%
3 Months
-32.42%
6 Months
-69.64%
1 Year
-89.12%
2 Year
-93.56%
Key data
Stock price
$0.84
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$0.55 - $7.45
52 WEEK CHANGE
-$0.89
MARKET CAP 
4.860 M
YIELD 
N/A
SHARES OUTSTANDING 
5.799 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.45
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$18,343
AVERAGE 30 VOLUME 
$38,745
Company detail
CEO: Robert Foster
Region: US
Website: http://contravir.com/
Employees: 22
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services

hepion pharmaceuticals, inc., a biopharmaceutical company, focuses on the development of pleiotropic drug therapy for the treatment of chronic liver diseases in the united states. it is involved in developing crv431, a cyclophilin inhibitor that has completed the phase i clinical trials for multiple biochemical pathways involved in the progression of liver diseases; and tenofovir exalidex, a lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the active antiviral agent tenofovir diphosphate for the treatment of hepatitis b. the company was formerly known as contravir pharmaceuticals, inc. and changed its name to hepion pharmaceuticals, inc. in july 2019. hepion pharmaceuticals, inc. was incorporated in 2013 and is headquartered in edison, new jersey.

Recent news